450 related articles for article (PubMed ID: 27496751)
1. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
2. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
[TBL] [Abstract][Full Text] [Related]
3. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
4. Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay.
Baumgartner CK; Zhang G; Kuether EL; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2015 Dec; 13(12):2210-9. PubMed ID: 26453193
[TBL] [Abstract][Full Text] [Related]
5. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
6. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
7. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
Cai Y; Shi Q
Front Immunol; 2020; 11():964. PubMed ID: 32595633
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.
Wang Y; Mao J; Li L; Xiao B; Ruan Z; Liu Y; Zhang G; Wang D; Mi JQ; Fang C; Xi X; Shi X; Wang J
Thromb Haemost; 2022 May; 122(5):755-766. PubMed ID: 34587639
[TBL] [Abstract][Full Text] [Related]
10. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
11. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
12. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
13. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.
Golder M; Mewburn J; Lillicrap D
Thromb Haemost; 2013 Jan; 109(1):53-60. PubMed ID: 23178924
[TBL] [Abstract][Full Text] [Related]
15. Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
Lyde RB; Ahn HS; Vo KK; Jarocha DJ; Tkaczynski J; Treffeisen E; Sullivan SK; Camire RM; Sabatino DE; French DL; Poncz M
Blood Adv; 2019 May; 3(9):1368-1378. PubMed ID: 31036722
[TBL] [Abstract][Full Text] [Related]
16. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.
Greene TK; Lyde RB; Bailey SC; Lambert MP; Zhai L; Sabatino DE; Camire RM; Arruda VR; Poncz M
J Thromb Haemost; 2014 Dec; 12(12):2102-12. PubMed ID: 25287191
[TBL] [Abstract][Full Text] [Related]
18. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
19. Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
Montgomery RR; Shi Q
Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S46-8. PubMed ID: 22421106
[TBL] [Abstract][Full Text] [Related]
20. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
